The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Lehigh Valley’s health networks are seeing abnormally high cases of the stomach bug that’s taking a large number of people ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Wisconsin Public Radio If you or someone in your family has been sick with a “stomach bug” lately, you’re not alone.

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...